-
1.发明申请PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF 审中-公开预防和/或预测生物标志物及其生物应用公开(公告)号：US20130281313A1
公开(公告)日：2013-10-24
申请号：US13819157
申请日：2011-09-01
IPC分类号： C12Q1/68 , G01N33/50 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/5011 , G01N33/5091 , G01N33/57496 , Y10T436/145555 , Y10T436/163333
摘要： The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs. Particular compounds capable to compensate, in a subject, an abnormal expression of one of the herein described products, in particular when the subject is exposed to a therapeutic treatment of cancer, thereby allowing or improving its efficiency in the subject, are also herein disclosed. Inventors, in addition, provide kits and DNA chips usable in the context of the present invention.
摘要翻译： 本发明涉及遗传学，免疫学和医学领域。 本发明更具体地涉及可以用于评估受试者中癌症预后的人类基因及其表达产物的鉴定，以评估受试者对癌症的治疗或监测的敏感性，特别是确定 在一段时间后这种治疗癌症的功效。 所述人基因和表达产物可以进一步用于（i）预防或治疗癌症，特别是确定或选择给定受试者和/或针对特定肿瘤的合适的癌症治疗，以及（ii） 筛选治疗活性药物。 在本文中还公开了能够在受试者中补偿本文所述产物之一的异常表达的特定化合物，特别是当受试者暴露于癌症的治疗性治疗从而允许或提高其在受试者中的效率时。 此外，发明人提供了可在本发明的上下文中使用的试剂盒和DNA芯片。
-
2.发明申请MSH2 AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER 审中-公开在非小细胞肺癌中的MSH2和ADJUVANT CISPLATIN基础化疗公开(公告)号：US20120004136A1
公开(公告)日：2012-01-05
申请号：US13256814
申请日：2010-03-19
申请人： Pierre Fouret , Jean-Charles Soria
发明人： Pierre Fouret , Jean-Charles Soria
IPC分类号： C40B30/04 , G01N33/566 , C40B40/10 , C12Q1/68 , C40B40/06
CPC分类号： G01N33/5748 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N2800/52
摘要： The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the MSH2 expression level in the biological sample containing tumor cells, and, optionally, the ERCC1 expression level.
摘要翻译： 本发明一般涉及一种诊断方法，用于预测诊断为癌症的受试者对基于铂化合物的辅助化学疗法的益处的益处，优选地以基于顺铂为基础的化学疗法，其实现了生物学中MSH2表达水平的测定 含有肿瘤细胞的样品，以及可选的ERCC1表达水平。
-
公开(公告)号：US10095829B2
公开(公告)日：2018-10-09
申请号：US13382585
申请日：2010-07-06
摘要： The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumor in an individual comprising the molecular characterization of the tumor, and the calculation of a score for the plurality of drugs essentially based on the percentage of deregulated target genes.
-
4.发明申请PARP AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER 审中-公开非小细胞肺癌中PARP和ADJUVANT基于CISPLATIN的化疗公开(公告)号：US20120277110A1
公开(公告)日：2012-11-01
申请号：US13386474
申请日：2010-07-26
CPC分类号： G01N33/57423 , G01N2333/91142 , G01N2800/52
摘要： The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the PARP expression level in the biological sample containing tumor cells, and, preferably, together with the MSH2 and/or ERCC1 expression level, more preferably together with the MSH2 and ERCC1 expression levels.
摘要翻译： 本发明一般涉及用于预测被诊断为癌症的受试者对基于铂化合物的辅助化疗的反应的益处的诊断方法，优选地以基于顺铂为基础的化学疗法，其实现了生物学中PARP表达水平的测定 含有肿瘤细胞的样品，优选与MSH2和/或ERCC1表达水平一起，更优选与MSH2和ERCC1表达水平一起。
-
公开(公告)号：US20090215090A1
公开(公告)日：2009-08-27
申请号：US12282522
申请日：2007-03-14
申请人： Pierre Fouret , Jean-Charles Soria
发明人： Pierre Fouret , Jean-Charles Soria
IPC分类号： G01N33/574
CPC分类号： C07K16/40 , G01N33/5011 , G01N33/57423 , G01N33/6872
摘要： The present invention concerns an in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy, said method comprising the step of the measurement of the ERCC1 protein by immunohistochemistry in a formalin-fixed paraffin-embedded tumor sample.
摘要翻译： 本发明涉及用于检测肿瘤细胞对化学疗法的易感性的体外方法，所述方法包括在福尔马林固定石蜡包埋的肿瘤样品中通过免疫组织化学测量ERCC1蛋白的步骤。
-
公开(公告)号：US09702875B2
公开(公告)日：2017-07-11
申请号：US14186285
申请日：2014-02-21
申请人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
发明人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
IPC分类号： G01N33/573 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/573 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57423 , G01N2800/52
摘要： An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
-
公开(公告)号：US20140170659A1
公开(公告)日：2014-06-19
申请号：US14186285
申请日：2014-02-21
申请人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
发明人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
IPC分类号： G01N33/573
CPC分类号： G01N33/573 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57423 , G01N2800/52
摘要： An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
-
8.发明申请EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY 审中-公开ERCC1的ISOFORM 202表达预测对癌症化疗的反应公开(公告)号：US20140120543A1
公开(公告)日：2014-05-01
申请号：US14021316
申请日：2013-09-09
申请人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
发明人： Ken Olaussen , Jean-Charles Soria , Luc Friboulet
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/573 , G01N2800/52 , G01N2800/7028
摘要： An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
摘要翻译： 公开了用于检测肿瘤细胞对化学疗法的敏感性的体外方法。 该方法包括测量ERCC1蛋白质的同种型202的表达水平的步骤。
-
公开(公告)号：US20120136583A1
公开(公告)日：2012-05-31
申请号：US13382585
申请日：2010-07-06
IPC分类号： G06F19/10
CPC分类号： G06F19/18 , G06F19/00 , G06F19/20 , G06F19/326 , G06F19/3456 , Y02A90/26
摘要： The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumour in an individual comprising the molecular characterization of the tumour, and the calculation of a score for the plurality of drug essentially based on the percentage of deregulated target gene.
摘要翻译： 本发明涉及一种用于预测多种用于治疗肿瘤的药物的相对功效的方法，所述药物包括肿瘤的分子表征，以及基于去调节靶标百分比计算多种药物的评分 基因。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
